Assessment the microbial contamination rate of re-used vials of bevacizumab(Avastin) and the risk of endophthalmitis.
Background: Introduction of anti-VEGF therapy has changed the way of management to the retinal diseases. Pegaptanib (Macugen)was the first to be approved and was followed by other agents, including ranibizumab (Lucentis, Genentech, San Francisco, Calif.), bevacizumab (Avastin, Genentech) and aflibe...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
university of basrah
2025-06-01
|
| Series: | Basrah Journal of Surgery |
| Subjects: | |
| Online Access: | https://bjsrg.uobasrah.edu.iq/article_188701.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|